| 3.34 -0.064 (-1.87%) | 11-11 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.66  |
1-year : | 5.3 |
| Resists | First : | 3.98 |
Second : | 4.53 |
| Pivot price | 3.5 |
|||
| Supports | First : | 3.09 | Second : | 2.57 |
| MAs | MA(5) : | 3.37  |
MA(20) : | 3.56 |
| MA(100) : | 3.95 |
MA(250) : | 4.95 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 31.6 |
D(3) : | 23.8 |
| RSI | RSI(14): 40.1 |
|||
| 52-week | High : | 22.39 | Low : | 2.29 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ BLRX ] has closed above bottom band by 23.8%. Bollinger Bands are 24.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.46 - 3.48 | 3.48 - 3.5 |
| Low: | 3.28 - 3.3 | 3.3 - 3.32 |
| Close: | 3.3 - 3.33 | 3.33 - 3.37 |
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
Mon, 29 Sep 2025
$3.8B Market Opportunity: BioLineRx's Novel Brain Cancer Drug GLIX1 Targets DNA Damage in Glioblastoma - Stock Titan
Thu, 21 Aug 2025
Earnings call transcript: BioLineRx Q2 2025 sees restructuring and innovation - Investing.com
Fri, 15 Aug 2025
BLRX: ASCO Poster & Abstract - Zacks Small Cap Research
Thu, 14 Aug 2025
BioLineRx Reports Second Quarter 2025 Financial Results and Provides Corporate Update - PR Newswire
Wed, 09 Jul 2025
Why Investors Shouldn't Be Surprised By BioLineRx Ltd.'s (TLV:BLRX) 29% Share Price Plunge - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 4 (M) |
| Shares Float | 2,450 (M) |
| Held by Insiders | 3.9 (%) |
| Held by Institutions | 1.5 (%) |
| Shares Short | 190 (K) |
| Shares Short P.Month | 171 (K) |
| EPS | -6 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -45.4 % |
| Operating Margin | -757.6 % |
| Return on Assets (ttm) | -15.4 % |
| Return on Equity (ttm) | -46 % |
| Qtrly Rev. Growth | -94.5 % |
| Gross Profit (p.s.) | 2.4 |
| Sales Per Share | 4.04 |
| EBITDA (p.s.) | -2.55 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -21 (M) |
| Levered Free Cash Flow | -12 (M) |
| PE Ratio | -0.56 |
| PEG Ratio | 0 |
| Price to Book value | 334 |
| Price to Sales | 0.82 |
| Price to Cash Flow | -0.68 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|